Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses

Bryce M. Warner, Derek R. Stein, Rohit Jangra, Megan M. Slough, Patrycja Sroga, Angela Sloan, Kathy L. Frost, Stephanie Booth, Kartik Chandran, David Safronetz

Research output: Contribution to journalArticle

Abstract

Andes virus (ANDV) and Sin Nombre virus (SNV) are the main causative agents responsible for hantavirus cardiopulmonary syndrome (HCPS) in the Americas. HCPS is a severe respiratory disease with a high fatality rate for which there are no approved therapeutics or vaccines available. Some vaccine approaches for HCPS have been tested in preclinical models, but none have been tested in infectious models in regard to their ability to protect against multiple species of HCPS-causing viruses. Here, we utilize recombinant vesicular stomatitis virus-based (VSV) vaccines for Andes virus (ANDV) and Sin Nombre virus (SNV) and assess their ability to provide cross-protection in infectious challenge models. We show that, while both rVSVΔG/ANDVGPC and rVSVΔG/SNVGPC display attenuated growth as compared to wild type VSV, each vaccine is able to induce a cross-reactive antibody response. Both vaccines protected against both homologous and heterologous challenge with ANDV and SNV and prevented HCPS in a lethal ANDV challenge model. This study provides evidence that the development of a single vaccine against HCPS-causing hantaviruses could provide protection against multiple agents.

Original languageEnglish (US)
JournalViruses
Volume11
Issue number7
DOIs
StatePublished - Jul 13 2019

Fingerprint

Sin Nombre virus
Cross Protection
Hantavirus
Vesicular Stomatitis
Vaccines
Viruses

Keywords

  • Andes virus
  • Hantavirus
  • hantavirus cardiopulmonary syndrome
  • prophylactic immunization
  • Sin Nombre virus
  • vaccination
  • vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses. / Warner, Bryce M.; Stein, Derek R.; Jangra, Rohit; Slough, Megan M.; Sroga, Patrycja; Sloan, Angela; Frost, Kathy L.; Booth, Stephanie; Chandran, Kartik; Safronetz, David.

In: Viruses, Vol. 11, No. 7, 13.07.2019.

Research output: Contribution to journalArticle

Warner, BM, Stein, DR, Jangra, R, Slough, MM, Sroga, P, Sloan, A, Frost, KL, Booth, S, Chandran, K & Safronetz, D 2019, 'Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses', Viruses, vol. 11, no. 7. https://doi.org/10.3390/v11070645
Warner, Bryce M. ; Stein, Derek R. ; Jangra, Rohit ; Slough, Megan M. ; Sroga, Patrycja ; Sloan, Angela ; Frost, Kathy L. ; Booth, Stephanie ; Chandran, Kartik ; Safronetz, David. / Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses. In: Viruses. 2019 ; Vol. 11, No. 7.
@article{5215a2f460e148c38b2b521228c42a64,
title = "Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses",
abstract = "Andes virus (ANDV) and Sin Nombre virus (SNV) are the main causative agents responsible for hantavirus cardiopulmonary syndrome (HCPS) in the Americas. HCPS is a severe respiratory disease with a high fatality rate for which there are no approved therapeutics or vaccines available. Some vaccine approaches for HCPS have been tested in preclinical models, but none have been tested in infectious models in regard to their ability to protect against multiple species of HCPS-causing viruses. Here, we utilize recombinant vesicular stomatitis virus-based (VSV) vaccines for Andes virus (ANDV) and Sin Nombre virus (SNV) and assess their ability to provide cross-protection in infectious challenge models. We show that, while both rVSVΔG/ANDVGPC and rVSVΔG/SNVGPC display attenuated growth as compared to wild type VSV, each vaccine is able to induce a cross-reactive antibody response. Both vaccines protected against both homologous and heterologous challenge with ANDV and SNV and prevented HCPS in a lethal ANDV challenge model. This study provides evidence that the development of a single vaccine against HCPS-causing hantaviruses could provide protection against multiple agents.",
keywords = "Andes virus, Hantavirus, hantavirus cardiopulmonary syndrome, prophylactic immunization, Sin Nombre virus, vaccination, vaccine",
author = "Warner, {Bryce M.} and Stein, {Derek R.} and Rohit Jangra and Slough, {Megan M.} and Patrycja Sroga and Angela Sloan and Frost, {Kathy L.} and Stephanie Booth and Kartik Chandran and David Safronetz",
year = "2019",
month = "7",
day = "13",
doi = "10.3390/v11070645",
language = "English (US)",
volume = "11",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

TY - JOUR

T1 - Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses

AU - Warner, Bryce M.

AU - Stein, Derek R.

AU - Jangra, Rohit

AU - Slough, Megan M.

AU - Sroga, Patrycja

AU - Sloan, Angela

AU - Frost, Kathy L.

AU - Booth, Stephanie

AU - Chandran, Kartik

AU - Safronetz, David

PY - 2019/7/13

Y1 - 2019/7/13

N2 - Andes virus (ANDV) and Sin Nombre virus (SNV) are the main causative agents responsible for hantavirus cardiopulmonary syndrome (HCPS) in the Americas. HCPS is a severe respiratory disease with a high fatality rate for which there are no approved therapeutics or vaccines available. Some vaccine approaches for HCPS have been tested in preclinical models, but none have been tested in infectious models in regard to their ability to protect against multiple species of HCPS-causing viruses. Here, we utilize recombinant vesicular stomatitis virus-based (VSV) vaccines for Andes virus (ANDV) and Sin Nombre virus (SNV) and assess their ability to provide cross-protection in infectious challenge models. We show that, while both rVSVΔG/ANDVGPC and rVSVΔG/SNVGPC display attenuated growth as compared to wild type VSV, each vaccine is able to induce a cross-reactive antibody response. Both vaccines protected against both homologous and heterologous challenge with ANDV and SNV and prevented HCPS in a lethal ANDV challenge model. This study provides evidence that the development of a single vaccine against HCPS-causing hantaviruses could provide protection against multiple agents.

AB - Andes virus (ANDV) and Sin Nombre virus (SNV) are the main causative agents responsible for hantavirus cardiopulmonary syndrome (HCPS) in the Americas. HCPS is a severe respiratory disease with a high fatality rate for which there are no approved therapeutics or vaccines available. Some vaccine approaches for HCPS have been tested in preclinical models, but none have been tested in infectious models in regard to their ability to protect against multiple species of HCPS-causing viruses. Here, we utilize recombinant vesicular stomatitis virus-based (VSV) vaccines for Andes virus (ANDV) and Sin Nombre virus (SNV) and assess their ability to provide cross-protection in infectious challenge models. We show that, while both rVSVΔG/ANDVGPC and rVSVΔG/SNVGPC display attenuated growth as compared to wild type VSV, each vaccine is able to induce a cross-reactive antibody response. Both vaccines protected against both homologous and heterologous challenge with ANDV and SNV and prevented HCPS in a lethal ANDV challenge model. This study provides evidence that the development of a single vaccine against HCPS-causing hantaviruses could provide protection against multiple agents.

KW - Andes virus

KW - Hantavirus

KW - hantavirus cardiopulmonary syndrome

KW - prophylactic immunization

KW - Sin Nombre virus

KW - vaccination

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85070465840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070465840&partnerID=8YFLogxK

U2 - 10.3390/v11070645

DO - 10.3390/v11070645

M3 - Article

C2 - 31337019

AN - SCOPUS:85070465840

VL - 11

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 7

ER -